| Note |
Open the way to antidepressant action. In agitated patients, surmontil (trimipramine maleate) relieves agitation and insomnia in just days. Rapid relief of agitation and/or insomnia… often in days. The anxiety survey inventory showed some depressed patients experienced significant (p<.01) relief from insomnia within days. Agitated/depressed patients may also experience symptomatic relief as rapidly. Unaltered REM patterns may allow for a more natural sleep. Unlike nearly all other tricyclics, surmontil has no effect upon REM sleep and does not cause significant change in EEG patterns during normal sleep. Dependable tricyclic efficacy. In separate clinical trials comparing surmontil to either amitriptyline of imipramine, researchers found no significant difference in terms of antidepressive efficacy among the three tricyclics. Well-established record of safety. Surmontil has consistently demonstrated a low incidence of adverse effects. And most patients tolerate it without difficulty in diagnoses of up to 300 mg/day. Minimal effect on normal cardiac function. The effect of surmontil upon normal cardiac function is minimal. Significant adverse reactions such as arrhythmias are infrequent. Rapid anxiolytic action in only days, without a benzodiazepine or a phenothiazine. Anxious depressives showed significant improvement (p,.05) in less than one week in terms of anxiousness as measured by the Hamilton Psychiatric Rating Scale of Depression. Nighttime dosage regimen effective after initial titration. Clinical trials have demonstrated that patients receiving a 150mg nighttime dose after a one-week titration period continued to show significant improvement over baseline, in terms of symptoms measures by the Hamilton depression/anxiety inventory |
